FORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Thomas B. King to its Board of Directors.
"I am pleased to welcome Thomas King to our Board of Directors," said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceuticals. "Tom is an exceptionally accomplished executive who has held leadership positions at life sciences companies over the last three decades. In addition, his extensive board experience will provide us with valuable insights and perspectives as we seek to advance our two lead candidates, TFF VORI and TFF TAC, into later-stage clinical testing."
"I am very excited to join the Board of TFF Pharmaceuticals at a time when the Company is demonstrating how its ground-breaking Thin Film Freezing technology can be applied in the clinic to address the significant unmet need in patients with rare diseases," said Mr. King. "I look forward to working alongside Harlan and our fellow Board members to help advance the company's mission of significantly improving new and existing therapies for the benefit of patients."
Mr. King has over 30 years of executive leadership and board experience in the life sciences industry. Presently, Mr. King sits on the board of several companies, including Achieve Life Sciences (NASDAQ:ACHV), Kinaset Therapeutics, and Concentric Analgesics. From 2003 to 2016, Mr. King served as the President, Chief Executive Officer and Director of Alexza Pharmaceuticals, where he led multiple stock offerings and debt transactions from 2003 through 2015 (IPO in 2006), raising in excess of $600mm and ultimately leading to the successful M&A transaction with Grupo Ferrer. Prior to joining Alexza, he was the President, Chief Executive Officer and Director of Cognetix, Inc. From 1994 to 2000, ...